BACKGROUND: The effectiveness of high-protein (HP) diets in reducing body weight and adiposity and potentially improving clinical outcomes in heart failure (HF) is not known. OBJECTIVE: This feasibility study was conducted to evaluate the impact of 3 dietary interventions on body weight and adiposity, functional status, lipid profiles, glycemic control, and quality of life (QOL) in overweight and obese patients with HF and type 2 diabetes mellitus. DESIGN:Fourteen patients with HF with a body mass index greater than 27 kg/m2 were randomized to an HP diet, a standard protein diet, or a conventional diet. Data were obtained at baseline and 12 weeks. RESULTS: There were no significant differences in age (59 +/- 10 years), sex (78% male), New York Heart Association class (43% class II, 57% class III), and HF etiology or left ventricular ejection fraction (26 +/- 7) between the groups at baseline. Patients on the HP diet demonstrated significantly greater reductions in weight (P = .005), percent body fat (P = .036), total cholesterol (P = .016), triglyceride concentrations (P = .034), and low-density lipoprotein cholesterol (P = .041) and greater improvements in functional status (6-minute walk [P = .010] and VO2 peak [P = .003]), high-density lipoprotein cholesterol (P = .006), and physical QOL scores (P = .022) compared with those on standard protein and conventional diets. CONCLUSION: A 12-week HP diet resulted in moderate weight loss and reduced adiposity in a small sample of overweight and obese patients with HF that were associated with improvements in functional status, lipid profiles, glycemic control, and QOL. However, these preliminary findings must be confirmed in studies with more participants and long-term follow-up.
RCT Entities:
BACKGROUND: The effectiveness of high-protein (HP) diets in reducing body weight and adiposity and potentially improving clinical outcomes in heart failure (HF) is not known. OBJECTIVE: This feasibility study was conducted to evaluate the impact of 3 dietary interventions on body weight and adiposity, functional status, lipid profiles, glycemic control, and quality of life (QOL) in overweight and obesepatients with HF and type 2 diabetes mellitus. DESIGN: Fourteen patients with HF with a body mass index greater than 27 kg/m2 were randomized to an HP diet, a standard protein diet, or a conventional diet. Data were obtained at baseline and 12 weeks. RESULTS: There were no significant differences in age (59 +/- 10 years), sex (78% male), New York Heart Association class (43% class II, 57% class III), and HF etiology or left ventricular ejection fraction (26 +/- 7) between the groups at baseline. Patients on the HP diet demonstrated significantly greater reductions in weight (P = .005), percent body fat (P = .036), total cholesterol (P = .016), triglyceride concentrations (P = .034), and low-density lipoprotein cholesterol (P = .041) and greater improvements in functional status (6-minute walk [P = .010] and VO2 peak [P = .003]), high-density lipoprotein cholesterol (P = .006), and physical QOL scores (P = .022) compared with those on standard protein and conventional diets. CONCLUSION: A 12-week HP diet resulted in moderate weight loss and reduced adiposity in a small sample of overweight and obesepatients with HF that were associated with improvements in functional status, lipid profiles, glycemic control, and QOL. However, these preliminary findings must be confirmed in studies with more participants and long-term follow-up.
Authors: R M Krauss; R H Eckel; B Howard; L J Appel; S R Daniels; R J Deckelbaum; J W Erdman; P Kris-Etherton; I J Goldberg; T A Kotchen; A H Lichtenstein; W E Mitch; R Mullis; K Robinson; J Wylie-Rosett; S St Jeor; J Suttie; D L Tribble; T L Bazzarre Journal: Circulation Date: 2000-10-31 Impact factor: 29.690
Authors: Gregg C Fonarow; Preethi Srikanthan; Maria Rosa Costanzo; Guillermo B Cintron; Margarita Lopatin Journal: Am Heart J Date: 2007-01 Impact factor: 4.749
Authors: Jonathan Buchanan; Pradip K Mazumder; Ping Hu; Gopa Chakrabarti; Matthew W Roberts; Ui Jeong Yun; Robert C Cooksey; Sheldon E Litwin; E Dale Abel Journal: Endocrinology Date: 2005-09-01 Impact factor: 4.736
Authors: Barry H Greenberg; William T Abraham; Nancy M Albert; Karen Chiswell; Robert Clare; Wendy Gattis Stough; Mihai Gheorghiade; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young; Gregg C Fonarow Journal: Am Heart J Date: 2007-08 Impact factor: 4.749
Authors: J D Krebs; C R Elley; A Parry-Strong; H Lunt; P L Drury; D A Bell; E Robinson; S A Moyes; J I Mann Journal: Diabetologia Date: 2012-04 Impact factor: 10.122
Authors: Marjan Motie; Lorraine S Evangelista; Tamara Horwich; Michele Hamilton; Dawn Lombardo; Dan M Cooper; Pietro R Galassetti; Gregg C Fonarow Journal: Contemp Clin Trials Date: 2013-08-17 Impact factor: 2.226
Authors: Tammy L Kindel; Tom Foster; Paul Goldspink; Steven J Kindel; John Corbett; Michael Widlanksy; Jennifer Strande Journal: Obes Surg Date: 2017-09 Impact factor: 4.129
Authors: Chris Adamopoulos; Philippe Meyer; Ravi V Desai; Kyparissi Karatzidou; Fernando Ovalle; Michel White; Inmaculada Aban; Thomas E Love; Prakash Deedwania; Stefan D Anker; Ali Ahmed Journal: Eur J Heart Fail Date: 2010-10-07 Impact factor: 15.534
Authors: Allison M Pritchett; Anita Deswal; David Aguilar; John P Foreyt; Wenyaw Chan; Douglas L Mann; Christie Ballantyne; Biykem Bozkurt Journal: J Obes Weight Loss Ther Date: 2012-03-15
Authors: Rogerio F Ribeiro; Erinne R Dabkowski; Kelly A O'Connell; Wenhong Xu; Tatiana de Fatima Galvao; Peter A Hecker; Kadambari C Shekar; Ivanita Stefanon; William C Stanley Journal: Appl Physiol Nutr Metab Date: 2013-09-11 Impact factor: 2.665